VanEck Biotech ETF
BBH
81 hedge funds and large institutions have $333M invested in VanEck Biotech ETF in 2015 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 8 closing their positions.
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 78 → 81 (+3)
7.08% less ownership
Funds ownership: 48.72% → 41.64% (-7.1%)
12% less capital invested
Capital invested by funds: $378M → $333M (-$44.9M)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
56% less call options, than puts
Call options by funds: $3.69M | Put options by funds: $8.31M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$17.2M |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$2.08M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$2.05M |
| 4 |
Citigroup
New York
|
+$1.67M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$902K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$52.5M |
| 2 |
VF
Virtu Financial
New York
|
-$15.8M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.84M |
| 4 |
Jane Street
New York
|
-$3.58M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.46M |
BBH Hedge Fund Activity: Q2 2015 in Review
81 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2015, worth a combined $333M — down 12% from $378M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BBH positions and 8 closed out — a net gain of 3 holders — while 23 added to existing stakes and 28 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $17.2M. The largest seller was Credit Suisse, cutting an estimated $52.5M.
- 81 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2015, up from 78 in Q1 2015.
- Funds reported $333M of VanEck Biotech ETF stock for Q2 2015, down 12% quarter-over-quarter.
- 11 funds opened new VanEck Biotech ETF positions in Q2 2015 and 8 closed out, a net change of +3 holders.
- The largest VanEck Biotech ETF buyer in Q2 2015 was Goldman Sachs, an estimated $17.2M added.
- The largest VanEck Biotech ETF seller in Q2 2015 was Credit Suisse, an estimated $52.5M sold.
Based on aggregated 13F filings for Q2 2015.